{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rivaroxaban+2.5+mg+Tablet",
    "query": {
      "intervention": "Rivaroxaban 2.5 mg Tablet"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 35,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rivaroxaban+2.5+mg+Tablet&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T16:13:24.232Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00440193",
      "title": "Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Venous Thrombosis"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin followed by VKA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3449,
      "start_date": "2007-03",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2014-02-27",
      "last_synced_at": "2026-09-27T16:13:24.232Z",
      "location_count": 23,
      "location_summary": "Little Rock, Arkansas • Redlands, California • Bay Pines, Florida + 18 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Redlands",
          "state": "California"
        },
        {
          "city": "Bay Pines",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00440193"
    },
    {
      "nct_id": "NCT00439725",
      "title": "Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1197,
      "start_date": "2007-02",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2014-11-04",
      "last_synced_at": "2026-09-27T16:13:24.232Z",
      "location_count": 25,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Redlands, California + 20 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Redlands",
          "state": "California"
        },
        {
          "city": "Bay Pines",
          "state": "Florida"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00439725"
    },
    {
      "nct_id": "NCT00362232",
      "title": "Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin",
          "type": "DRUG"
        },
        {
          "name": "Placebo: tablet of Rivaroxaban",
          "type": "DRUG"
        },
        {
          "name": "Placebo: syringes of Enoxaparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3148,
      "start_date": "2006-06",
      "completion_date": "2008-01",
      "has_results": true,
      "last_update_posted_date": "2014-11-04",
      "last_synced_at": "2026-09-27T16:13:24.232Z",
      "location_count": 40,
      "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 36 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00362232"
    },
    {
      "nct_id": "NCT01684423",
      "title": "Oral Rivaroxaban in Children With Venous Thrombosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Venous Thrombosis"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Active comparator",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban (BAY59-7939) suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 64,
      "start_date": "2013-02-19",
      "completion_date": "2016-09-01",
      "has_results": true,
      "last_update_posted_date": "2017-09-21",
      "last_synced_at": "2026-09-27T16:13:24.232Z",
      "location_count": 13,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Orange, California + 10 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01684423"
    },
    {
      "nct_id": "NCT02111564",
      "title": "A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heart Failure",
        "Respiratory Insufficiency",
        "Stroke Acute",
        "Infectious Diseases",
        "Rheumatic Diseases"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban, 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban, 7.5 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 12024,
      "start_date": "2014-01-07",
      "completion_date": "2018-05-03",
      "has_results": true,
      "last_update_posted_date": "2019-11-25",
      "last_synced_at": "2026-09-27T16:13:24.232Z",
      "location_count": 135,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 132 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02111564"
    },
    {
      "nct_id": "NCT00571649",
      "title": "Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban placebo",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 8101,
      "start_date": "2007-12",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2016-09-15",
      "last_synced_at": "2026-09-27T16:13:24.232Z",
      "location_count": 121,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 107 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Geneva",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00571649"
    },
    {
      "nct_id": "NCT01464450",
      "title": "Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics",
        "Bioavailability",
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Scientific Affairs, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 55,
      "start_date": "2011-10",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2017-01-24",
      "last_synced_at": "2026-09-27T16:13:24.232Z",
      "location_count": 1,
      "location_summary": "Neptune City, New Jersey",
      "locations": [
        {
          "city": "Neptune City",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01464450"
    },
    {
      "nct_id": "NCT00403767",
      "title": "An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atrial Fibrillation",
        "Stroke",
        "Embolism"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        },
        {
          "name": "Matching placebo for Rivaroxaban arm (Warfarin placebo)",
          "type": "DRUG"
        },
        {
          "name": "Matching placebo for Warfarin arm (Rivaroxaban placebo)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14269,
      "start_date": "2006-12",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2014-04-29",
      "last_synced_at": "2026-09-27T16:13:24.232Z",
      "location_count": 295,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 292 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Geneva",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Pell City",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00403767"
    },
    {
      "nct_id": "NCT01830543",
      "title": "A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atrial Fibrillation",
        "Percutaneous Coronary Intervention"
      ],
      "interventions": [
        {
          "name": "rivaroxaban 2.5 mg",
          "type": "DRUG"
        },
        {
          "name": "rivaroxaban 15 mg",
          "type": "DRUG"
        },
        {
          "name": "rivaroxaban 10 mg",
          "type": "DRUG"
        },
        {
          "name": "aspirin (ASA)",
          "type": "DRUG"
        },
        {
          "name": "vitamin K antagonist (VKA)",
          "type": "DRUG"
        },
        {
          "name": "clopidogrel",
          "type": "DRUG"
        },
        {
          "name": "prasugrel",
          "type": "DRUG"
        },
        {
          "name": "ticagrelor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Scientific Affairs, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2124,
      "start_date": "2013-05-10",
      "completion_date": "2016-07-28",
      "has_results": true,
      "last_update_posted_date": "2017-09-19",
      "last_synced_at": "2026-09-27T16:13:24.232Z",
      "location_count": 86,
      "location_summary": "Huntsville, Alabama • Los Alamitos, California • Mission Viejo, California + 83 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01830543"
    },
    {
      "nct_id": "NCT00329628",
      "title": "Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4541,
      "start_date": "2006-02",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2014-10-28",
      "last_synced_at": "2026-09-27T16:13:24.232Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Northport, Alabama • Phoenix, Arizona + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Northport",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Benton",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00329628"
    }
  ]
}